Evidence map›Paper›PMID 31796542›Full record

ArticlemBio2019

Simian Immunodeficiency Virus Infection of Rhesus Macaques Results in Delayed Zika Virus Clearance.

Carol L Vinton, Samuel J Magaziner, Kimberly A Dowd, Shelly J Robertson, Emerito Amaro-Carambot, Erik P Karmele, Alexandra M Ortiz, Carly E Starke, Joseph C Mudd, Stephen S Whitehead and 4 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Carol L VintonBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Samuel J MagazinerViral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology & Microbiology, NIAID/NIH, Bethesda, Maryland, USA.
Kimberly A DowdViral Pathogenesis Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Shelly J RobertsonInnate Immunity & Pathogenesis Section, Laboratory of Virology, NIAID/NIH, Hamilton, Montana, USA.
Emerito Amaro-CarambotViral Pathogenesis Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Erik P KarmeleMucosal Immunobiology Section, Laboratory of Molecular Immunology, NIAID/NIH, Bethesda, Maryland, USA.
Alexandra M OrtizBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Carly E StarkeBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Joseph C MuddBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Stephen S WhiteheadViral Pathogenesis Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Sonja M BestInnate Immunity & Pathogenesis Section, Laboratory of Virology, NIAID/NIH, Hamilton, Montana, USA.
Theodore C PiersonViral Pathogenesis Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA.
Heather D HickmanViral Immunity and Pathogenesis Unit, Laboratory of Clinical Immunology & Microbiology, NIAID/NIH, Bethesda, Maryland, USA.
Jason M BrenchleyBarrier Immunity Section, Laboratory of Viral Diseases, NIAID/NIH, Bethesda, Maryland, USA jbrenchl@mail.nih.gov.
National Institute of Allergy and Infectious Diseases · USNational Institutes of Health · US

Funding

Mechanisms of Immune Activation and Disease Progression in Animal ModelsZ01AI001029 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BRENCHLEY, JASON · 2008 to 2008
$455k
Intramural NIH HHS Z01 AI001029
6 · The paper itself

Abstract

Flaviviruses are controlled by adaptive immune responses but are exquisitely sensitive to interferon-stimulated genes (ISGs). How coinfections, particularly simian immunodeficiency viruses (SIVs), that induce robust ISG signatures influence flavivirus clearance and pathogenesis is unclear. Here, we studied how Zika virus (ZIKV) infection is modulated in SIV-infected nonhuman primates. We measured ZIKV replication, cellular ZIKV RNA levels, and immune responses in non-SIV-infected and SIV-infected rhesus macaques (RMs), which we infected with ZIKV. Coinfected animals had a 1- to 2-day delay in peak ZIKV viremia, which was 30% of that in non-SIV-infected animals. However, ZIKV viremia was significantly prolonged in SIV-positive (SIV

Indexed as

AnimalsAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsFemaleInterferonsMacaca mulattaMaleSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadViremiaVirus ReplicationZika VirusZika Virus InfectionAntibodies, NeutralizingAntibodies, ViralAntiviral AgentsInterferonsinnate immunitySIVtype I interferonZIKV

Identifiers

PMID31796542
PMCPMC6890994
OpenAlexW2993608904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.